Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Alston CL, et al
The company is advancing next-generation oral and injectable treatments and raised $411M in an oversubscribed Series A round, co-led by Forbion and General Atlantic, with participation from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital
NICE guidance specifies that treatment should be time-limited in the NHS setting
The majority of GLP-1 medications are only approved for adults 18 years and older
The valuation was north of $500,000,000, indicating investor interest
US$ 21.67
US$ 24.25
US$ 23.41
US$ 28.56
US$ 25.08
